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Abstract
Background: Bevacizumab has an important role in first-line treatment of metastatic colorectal cancer. However,
clinical trials studying its effect have involved distinct chemotherapy regimens with divergent results. The aim of
this meta-analysis is to gather current data and evaluate not only the efficacy of bevacizumab, but also the impact
of divergent backbone regimens.
Methods: A wide search of randomized clinical trials using bevacizumab in first-line metastatic colorectal cancer
was performed in Embase, MEDLINE, LILACS and Cochrane databases. Meeting presentations and abstracts were
also investigated. The resulting data were examined and included in the meta-analysis according to the type of
regimen.
Results: Six trials, totaling 3060 patients, were analyzed. There was an advantage to using bevacizumab for overall
survival (OS) and progression-free survival (PFS) (HR = 0.84; CI: 0.77-0.91; P < 0.00001 and HR = 0.72; CI: 0.66-0.78;
P < 0.00001, respectively). However, heterogeneity of results was very high for both outcomes, and subgroup
analyses supported the OS advantage with bevacizumab restricted to irinotecan-based regimens. Infusional
fluorouracil subsets involved a minor proportion, and did not demonstrate statistical benefit in PFS or OS.
Regarding toxicity, higher rates of grades 3-4 hypertension, bleeding, thromboembolic events and proteinuria were
uniformly observed with bevacizumab, leading to increased treatment interruptions (HR = 1.47; P = 0.0004).
Conclusions: Bevacizumab has efficacy in first-line treatment of advanced colorectal cancer, but the current data
are insufficient to support efficacy in all regimens, especially infusional fluorouracil regimens, like FOLFIRI and
FOLFOX.
Background
Colorectal cancer is currentlyt h et h i r dm o s td i a g n o s e d
cancer in men and the second in women worldwide, with
an estimate of over 1.2 million new cases and 608,700
deaths in 2008 [1]. In the attempt of disease control, target
therapy has been a matter of extensive research. Anti-
angiogenesis is one of the pivotal theories involved in this
approach, ever since the discovery of increased vascularity
as a probable key for tumour progression [2,3]. One of the
main pathways associated with the anti-angiogenic process
is the vascular endothelial growth factor (VEGF) family,
with high expression of its receptors observed not only in
colorectal neoplasms, but in a wide variety of distinct
tumours [4]. This fact led to the development of many
VEGF inhibitors, amongst which bevacizumab is one of
the most common.
Bevacizumab in colorectal cancer was studied initially in
the metastatic setting, and was approved by US Food And
Drug Administration (FDA) in 2004, based on a survival
benefit noted in the AVF2107 trial [5] with the Saltz’ irino-
tecan, 5-fluorouracil and leucovorin (IFL) regimen [6].
However, a similar benefit was not seen in the recent
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any medium, provided the original work is properly cited.single-centre randomised trial by Stathopoulos et al, ana-
lysing bevacizumab with irinotecan and bolus fluorouracil
[7].
Other recent trials have also failed to demonstrate the
same statistically significant results in survival, particu-
larly with other backbone regimens, such as isolated
capecitabine or oxaliplatin-containing regimens. One of
the most mentioned studies regarding oxaliplatin-based
chemotherapy is a prospective, double-blind randomised
trial of 1400 patients evaluating bevacizumab and the
FOLFOX or XELOX regimen in first-line treatment [8].
The results of this study confirmed a significant relative
benefit of 17% for disease-free survival, but overall survi-
val (OS) did not achieve statistical significance. Cur-
rently, the benefit on OS with the use of oxaliplatin is
limited to the second-line setting, applying higher doses
of bevacizumab [9].
Therefore, the use of bevacizumab in colorectal meta-
static disease has been a topic of much debate. All studies
available so far, when analysed individually, were unable to
reach the same conclusion. Thus, cost-effectiveness is also
unclear. This has led to distinct practice guidelines from
country-to-country, according to reimbursement policies
[10]. Probable causes for such conflict could be the una-
vailability of an optimal, standard therapy for this disease,
to which a comparison of bevacizumab would facilitate
m o r ea c c u r a t ed a t a[ 1 1 ] .M o r e o v e r ,t h ei n t r o d u c t i o ni n
clinical practice of cetuximab [12-14] and panitumumab
[15], monoclonal antibodies against epidermal growth fac-
tor receptor (EGFR), raised more questions concerning
which target agent should be preferred in the first-line
approach.
With the advent of new randomised trials, the objective
of this meta-analysis is to gather current data and evaluate
the effect of bevacizumab in first-line therapy, focusing on
each backbone regimen.
Methods
Search Strategy
Articles published or presented from August 2002 to
March 2011 were identified by a thorough investigation
of electronic databases including PubMed/MEDLINE,
EMBASE, LILACS, and The Cochrane Library. Meeting
websites from ASCO, ESMO, and the World Congress
on Gastrointestinal Cancer from 2005 to 2011 were
also examined. A sensitive search strategy was per-
formed through terms related to colorectal neoplasms,
bevacizumab,a n drandomised trials in all fields. There
were no limits established for language, methodological
characteristics or year of publication. Lists of refer-
ences from relevant articles were scanned and all addi-
tional studies of potential interest were retrieved for
further analysis.
Selection Criteria
The goal of this study was to identify all published ran-
domised, controlled clinical trials with a corresponding
design of comparison to chemotherapy with or without
bevacizumab for metastatic colorectal cancer, in pre-
viously untreated patients. To avoid bias related to drug
interactions, studies involving the use of other targeted
agents were excluded.
Two reviewers (LTM, ADS) examined the list of refer-
ences and individually selected the studies. A meeting
was then held to achieve consensus.
Data Extraction
For distinguishing purposes, the name of the first author
and the year of publication of the article were indicated.
Two reviewers (LTM, ABL) independently extracted the
data from all selected trials. A third reviewer (ADS) was
consulted in case of divergence.
OS and progression-free survival (PFS) were the main
outcomes analyzed. Other points of interest were objec-
tive response rate (ORR) and toxicity, measured by the
Common Toxicity Criteria (CTC) scale and retrieved as
published.
The preferred method of data extraction was to directly
collect the original hazard ratios (HR) described in each
study. If data reported were insufficient, the corresponding
authors were contacted with a request for the pending
information. Alternatively, data could be estimated indir-
ectly applying either the reported number of events and
the corresponding P-value for the log-rank statistics, or by
transcription of survival curves as suggested by Parmar
and colleagues [16]. In this case, calculations were made
through a spreadsheet provided by Tierney and colleagues
[17]. The original survival curves from electronic publica-
tions were enlarged so that reading errors could be pre-
vented, and data extraction was based on reading off
electronic coordinates for each variable.
Statistical Analysis and Synthesis
Two reviewers (LTM, ABL) extracted details regarding
methodological dimensions empirically linked to bias as
described by Deeks and colleagues [18]. Special focus was
given to the availability of information about the sequence
of randomisation, blinding and existence of placebo, the
intention-to-treat analysis (ITT), and the source of fund-
ing. According to the resulting data, the methodological
quality of each trial was validated. These details were then
applied in subgroups, and sensitivity analyses were per-
formed to test the stability of conclusions.
Meta-analyses for this study were conducted with Rev-
Man 5.0 software (Cochrane Collaboration’s Information
Management System). Analyses of data consisted of HR
for time-to-event outcomes comparisons, and odds ratio
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Page 2 of 8(OR) for dichotomous variables for which 95% confi-
dence intervals (CI) were calculated and presented in
forest plots. The diamond at the bottom of the plot
summarizes the best estimate of pooled valid outcomes
(the width representing its corresponding 95% CI). The
effect of the treatment for each single study was
expressed as a ratio of the bevacizumab-containing arm
over the chemotherapy alone arm. A HR value of less
t h a no n ea n da nO Rv a l u eo fm o r et h a no n em e a n ta
benefit for the association of bevacizumab.
Statistical heterogeneity was evaluated through chi-
square test [19], and expressed in I
2 index, as described
by Higgins and colleagues [20]. If heterogeneity was
detected (I
2 > 35%), a possible explanation for it was
investigated. An individuala n a l y s i sw a sp e r f o r m e di n
the presence of a detectable cause, otherwise data were
preferably not pooled. Publication bias was evaluated
according to Egger’s test [18].
Results and Discussion
Search Results
The literature search, involving articles published from
August 2002 to March 2011, generated 7 potential trials
[21-27]. One study was not included since it was written
in Chinese, and its full text was not available in press
[27]. The selection procedure is further summarized in
Figure 1. A total of two phase II and four phase III trials
were incorporated, comprising 3060 enrolled patients.
Table 1 describes the main details of the selected studies.
Progression-free Survival
From the six trials selected, five included the related
data, totalling 2938 patients. The association of bevaci-
zumab demonstrated uniform benefit (HR = 0.72; 95%
CI: 0.66-0.78; P < 0.00001) although high heterogeneity
between trials was observed (I² = 69%; P = 0.01).
For better interpretation of this discrepancy, subgroup
analyses were performed according to the chemotherapy
regimen studied.
The first comparison, sorted by cytotoxic agents
(Figure 2A), demonstrated an advantage of bevacizumab
with either 5-FU monotherapy or irinotecan-based che-
motherapy, while oxaliplatin -based treatment, though
beneficial, was less intense. The difference between sub-
groups was further confirmed by the statistical signifi-
cant heterogeneity (I² = 82.9%; P = 0.003).
Figure 1 Selection of included trials.
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pyrimidine administration (Figure 2B), in which the
NO16966 study was divided into its XELOX and FOLFOX
subsets. In this case, PFS was significantly favorable for
bolus 5-FU studies (HR = 0.63; 95% CI: 0.56-0.72; P <
0.00001; heterogeneity: I² = 16%; P = 0.30) as well as cape-
citabine regimens (HR = 0.72; 95% CI: 0.62-0.83; P <
0.00001; heterogeneity: I² = 44%; P = 0.18). Infusional 5-
FU, however, in the single subgroup analysis of FOLFOX,
did not present statistical advantage (HR = 0.89; 95% 95%
CI: 0.74-1.06; P = 0.18).
Overall Survival
With regards to OS, only one study [21] did not access
this outcome and was excluded. The results indicated an
advantage to the use of bevacizumab (HR = 0.84; 95% CI:
0.77-0.91; P < 0.00001), though heterogeneity was also
observed (I² =6 0 % ;P=0 . 0 4 ) .
In the cytotoxic agent subgroup evaluation (Figure 3A),
despite conflicting results between both trials involved
(I² = 87%; P = 0.006), the increment in OS occurred only
for irinotecan-based regimens (HR = 0.78; 95% CI: 0.68-
0.89; P = 0.0002), owing to the influence of one single
Table 1 Trial Characteristics
Irinotecan-based Oxaliplati n-based Fluorouracil alone
Study Hurwitz,
2004
(AVF2107)
[26]
Stathopoulos, 2010 [24] Saltz, 2008 (NO16966)
[25]
Kabinnavar, 2003 [21] Kabinnavar,
2005 [22]
Tebutt,
2010 (MAX)
[23]
No. of patients
(placebo/bev)
411/402 108/114 701/699 36/68 105/104 156/156
Phase III III III II II III
Randomization Adequate Adequate Adequate Adequate Adequate Unclear
Study
Population
First-line First-line First-line First-line First-line,
elderly
First-line,
elderly
ITT Analysis Yes No Yes No Yes Yes
Blinding Yes No Yes No Yes Yes
Multicentric Yes No Yes Yes Yes Yes
Alpha error Yes Yes Yes NS Yes Yes
Beta error Yes Yes Yes NS Yes Yes
Withdrawals NS Described Described Described Described Described
Regimens Saltz IFL Irino 135 mg/m2 + 5 FU
500 mg/m2 + LV 200 mg/
m2 every 21 d
XELOX or FOLFOX4 Roswell- Park Roswell- Park Capecitabine
Bev schedule 5 mg/kg
every 14 d
7.5 mg/kg every 21 d 7.5 mg/kg every 21 d
(XELOX) or 5 mg/kg every
14 d (FOLFOX4)
10 mg/kg every 14 d (32
patients) 5 mg/kg every 14
d (33 patients)
5 mg/kg
every 14 d
7.5 mg/kg
every 21 d
Maintenance Until
Progression
Until Progression Until Progression 48 Weeks Until
Progression
Until
Progression
Sponsor Industry NS Industry NS Public Public/
Industry
Description of the main trials’ characteristics and details prompt to bias.
Abbreviations: 5FU: fluorouracil; bev: Bevacizumab; d: days; Irino: Irinotecan; ITT: Intention to Treat; LV: leucovorin; NS: not stated.
Figure 2 Progression-free survival. Progression-free survival in subgroup analyses per type of cytotoxic agent associated (A) and type of
fluoropyrimidine administration (B).
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based treatments presented statistically significant data.
Regarding the type of fluoropyrimidine administration
(Figure 3B), bolus 5-FU (HR = 0.78; 95% CI: 0.69-0.88;
P < 0.00001) and capecitabine schemes (HR = 0.85; 95%
CI: 0.74-0.99; P = 0.03) were beneficial. The single sub-
set of infusional 5-FU did not reach significance.
Overall Response Rate
In contrast to the previous outcomes, the meta-analysis
of data involving ORR did not demonstrate favourable
overall results (OR = 1.12; 95% CI: 0.94-1.33; P = 0.21).
Fluorouracil monotherapy, on the other hand, was the
only subset with statistical significance, demonstrating a
higher ORR with the addition of bevacizumab (OR =
1.58; P = 0.02). All subgroup rates are further described
in Figure 4A and 4B.
Treatment-related Toxicity
In contrast to PFS or OS, results regarding toxicity were
not heterogeneous, with I
2 indexes ranging from 0% to
20% (Figure 5). The addition of bevacizumab was linked
to increase rates of hypertension, proteinuria, bleeding
and thromboembolic events, also leading to a slight
increment on treatment interruptions (HR = 1.47; 95%
CI: 1.19-1.83; P = 0.0004), particularly higher in the
oxaliplatin-containing study [25]. Other variables, such as
hematologic toxicity and gastrointestinal perforation,
were not statistically significant.
Treatment-related mortality, in this specific study for
first-line therapy, was not significantly influenced by the
addition of bevacizumab.
Conclusions
Several randomised trials have tested bevacizumab in
diverse combinations of oxaliplatin, irinotecan, 5-FU or
capecitabine. By analysing these data, it is possible to
observe high heterogeneity amongst studies. There are
two hypotheses to explain these differences: firstly, the fact
that trials being as divergent in their results as in their
designs (number of patients, selection criteria, bevacizu-
mab dose) could influence the data and consequently
introduce bias. The second explanation is a possible inter-
action of cytotoxic agents with VEGF-inhibitors like
bevacizumab.
Evidence to support this second hypothesis is evident in
the subgroup analyses of this study. Irinotecan based-regi-
mens appear to be the most advantageous with regards to
OS. The first study to evaluate this combination, AVF2107
[5], enrolled 813 patients in a double-blind, randomised
phase III study involving IFL regimen, and revealed a clear
advantage on OS (4.7 months) as well as PFS with the
Figure 3 Overall survival. Overall survival in subgroup analyses per type of cytotoxic agent associated (A) and type of fluoropyrimidine
administration (B).
Figure 4 Overall response rate. Overall response rate in subgroup analyses per type of cytotoxic agent associated (A) and type of
fluoropyrimidine administration (B).
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sequent study failed to demonstrate the same response pat-
tern. The recent single-centre randomised trial by
Stathopoulos et al [7] with 222 patients, compared the
combination of bevacizumab at 7.5 mg/kg to a bolus regi-
men of irinotecan and fluorouracil, both every 21 days.
Though the limitations of this trial should not be taken
aside (single-centre, unblinded, and a particular irinotecan-
b a s e dr e g i m e n ) ,O Sa n dO R Rw e r en o ta d v a n t a g e o u si n
the regimen. It is also important to consider that current
studies indicate infusional 5-FU regimens like FOLFIRI to
be more beneficial than IFL. The protocol amendment
from BICC-C, a trial originally planned to compare distinct
irinotecan-based therapies, randomised 117 patients to
FOLFIRI plus bevacizumab, 5 mg/kg every 2 weeks, or IFL
plus bevacizumab, 7.5 mg/kg every 3 weeks [28]. Updated
analyses described a significant superiority on OS (28
months v 19.8 months; P = 0.037) for the infusional treat-
ment, versus bolus regimen, at the cost of increased grade
3/4 hypertension (12.5% v 1.7%). Whether the presence of
Figure 5 Meta-analysis of toxicity.
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should be the extent of such benefit are still uncertain
issues.
Regarding oxaliplatin-based therapies, results are even
more contradictory. In the first-line setting, there is only
increased PFS supported by the single-study NO16966 [8],
in the XELOX subgroup. The same marginal benefit in
PFS without impact in OS from oxaliplatin association
seems to extend to other trials involving VEGF-inhibitors.
Two recent studies associating PTK/ZK, an oral antibody,
to FOLFOX in first- [29] and second-line therapies [30],
and one trial with the addition of the multikinase inhibitor
cediranib to FOLFOX or XELOX [31], presented a similar
pattern of results. This evidence could reinforce the
impression that oxaliplatin might not be an ideal partner
for such target inhibitors. Nonetheless, there are studies
indicating otherwise. The E3200 trial [9] evaluated the
addition of bevacizumab, with a higher dose of 10 mg/kg,
to the FOLFOX4 scheme. Amongst 829 patients enrolled
for second-line treatment, this study demonstrated statisti-
cally significant gain on OS (10.8 v 12.9 months; P =
0.0011) as well as ORR (8.6% v 22.7%). Thus, data available
are insufficient to reach a conclusion about whether the
addition of bevacizumab to an oxaliplatin-based regimen,
especially with FOLFOX, could be beneficial in che-
motherapy-naive patients.
Furthermore, when combined only with 5-FU, bevacizu-
mab demonstrated the highest benefit in PFS, despite the
absence of significant results for OS, in the subgroup
meta-analysis previously presented. In contrast to the
other agent subsets, no heterogeneity was observed. This
effect over PFS without impact on survival could be
explained by the selected population, restricted to the
elderly, usually unfit for other combination therapies.
The addition of bevacizumab to palliative chemotherapy
in advanced colorectal cancer is a paradigm left unsolved.
The overall benefit of such combination was already
attested in three global meta-analyses previously pub-
lished. The two first major systematic reviews assessed five
trials either in first- or second-line settings [32,33]. A com-
parison performed by Welch and colleagues in 2010 [33]
demonstrated significant reduction in mortality (HR =
0.79; 95% CI: 0.69-0.90; P = 0.0005), as well as progression
(HR = 0.63; 95% CI: 0.49-0.81; P = 0.0004), reass!uring the
former findings from the first published meta-analysis, by
Cao and colleagues [32]. With the advent of one new ran-
domised trial, a subsequent global review was repeated by
Galfrascoli et al [34], maintaining global benefit observed
in OS and PFS.
The delicate point of discussion from all those former
systematic reviews is that this advantage is not uniform.
Individual results are contradictory when assessed in par-
ticular, since the regimens of comparison are distinct.
Most trials have failed to prove statistical benefit for
survival, in light of the incremental cost and toxicity.
Considering that those differences should not be underes-
timated, the main focus of this current meta-analysis was
the separate comparison of backbone chemotherapies,
according to cytotoxic elements involved and pattern of
5-FU administration.
Although the present study did not show higher fatal
adverse events, a recent meta-analysis involving 16 clini-
cal trials with bevacizumab for solid tumours described
a significant increase in treatment-related mortality rate
(2.5% v 1.7%; P = 0.01), particularly in association to
taxanes and platinum agents (RR = 3.49; 95% CI: 1.82-
6.66; incidence, 3.3% vs 1.0%) [35].
These divergent results led to distinctly different prac-
tices throughout health systems: whereas bevacizumab is
approved for management of metastatic colorectal neo-
plasm by the FDA and European Medicines Agency
(EMA), guidance recently published from the United
Kingdom’s National Institute for Health and Clinical
Excellence (NICE) according to data and cost analyses,
indicates a refusal to approve the use of such medication.
All studies currently available, including the overall
results of this meta-analysis, lead to the conclusion that
bevacizumab is an effective agent for first-line treatment
for metastatic colorectal cancer. Nevertheless, its effective-
ness is observed in limited subsets as bolus fluorouracil,
capecitabine-regimens, and in combination with irinotecan.
Further studies involving infusional chemotherapy and
oxaliplatin combinations are required to better characterize
the pharmacological interference from companion agents.
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